Clinical trial
Effect of Depo-Medrol Application on the Psoas Muscle After Transpsoas LLIF on Post-operative Hip Flexor Weakness, Thigh Pain and Numbness
Name
23-090-2
Description
The goal of this study is to determine the effects of a corticosteroid administered to the psoas muscle following a transpsoas lateral lumbar interbody fusion (LLIF) on postoperative hip flexor weakness and thigh pain and numbness.
Trial arms
Trial start
2023-05-12
Estimated PCD
2025-08-01
Trial end
2027-05-01
Status
Recruiting
Phase
Early phase I
Treatment
Depo-Medrol
steroid
Arms:
Test group (standard care + study intervention)
Gel-Flow NT
hemostatic agent
Arms:
Control group (standard care), Test group (standard care + study intervention)
Size
80
Primary endpoint
Quantify the difference in thigh pain measured on the visual analog pain scale (VAS) between those receiving a depo-medrol injection and those who did not over 3 postoperative time periods: 2-3, 6, and 12 weeks following surgery.
2-3 weeks following surgery
Quantify the difference in thigh pain measured on the visual analog pain scale (VAS) between those receiving a depo-medrol injection and those who did not over 3 postoperative time periods: 2-3, 6, and 12 weeks following surgery.
6 weeks following surgery
Quantify the difference in thigh pain measured on the visual analog pain scale (VAS) between those receiving a depo-medrol injection and those who did not over 3 postoperative time periods: 2-3, 6, and 12 weeks following surgery.
12 weeks following surgery
Eligibility criteria
Inclusion Criteria:
* Patients from the practices of Drs. Singh, Mallozzi, Moss
* Transpsoas (PTP or LTP) lateral lumbar interbody fusion (LLIF) 1-3 disc levels with posterior instrumentation (Open or MIS) with or without laminectomy, must include L3-4 and/or L4-5
* Patients who agree to be a part of the study
* Patients with lumbar disc degeneration
* Patients between ages of 18 and 75
Exclusion Criteria:
* Scoliosis \>10°
* Spondylolisthesis \>Grade 1
* Flatback deformity
* Patients with insulin dependent diabetes
* Patients with \>3 levels of fusion
* Alternative interbodies
* Chronic oral steroid users
* Patients with allergy/intolerance to depo-medrol or other steroids
* Patients requiring bilateral transpsoas approaches
* Patients with ipsilateral symptomatic hip pathology
* Revision fusion procedures
* Cases involving trauma, tumor, or infection
* Patient's not capable of providing consent themselves
* Non-fluent English speakers (for consenting reasons)
* Patients who are lost to follow-up before the two year follow up period
Protocol
{'studyType': 'INTERVENTIONAL', 'phases': ['PHASE4'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'OTHER', 'maskingInfo': {'masking': 'SINGLE', 'whoMasked': ['PARTICIPANT']}}, 'enrollmentInfo': {'count': 80, 'type': 'ESTIMATED'}}
Updated at
2023-07-03
1 organization
2 products
5 indications
Organization
Hardeep SinghProduct
Depo-MedrolIndication
Muscle WeaknessIndication
PainIndication
PostoperativeIndication
ParesthesiaIndication
MuscleProduct
Gel-Flow NT